/PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) will present new data across its dermatology portfolio at the 2026 Fall Clinical Dermatology Conference...

Eli Lilly and Company CEO Dave Ricks tells CNBC-TV18

Las acciones de Eli Lilly cotizan a 1.016,60 EUR en las operaciones del fin de semana del 4 de octubre de 2026. Eso coincide con los 1.016 EUR.

Jaypirca obtiene la aprobación de primera línea para CLL/SLL para adultos sin deleción conocida de 17p después de que un ensayo con 282 pacientes mostrara un índice de riesgo de 0,20.

Eli Lilly and Company (NYSE:LLY) has carved out a strong position in the pharmaceutical industry, with much of its competitive advantage now tied to its leadership in diabetes and obesity treatments. The company’s moat comes from several factors working together: drug innovation, patent protection, manufacturing capacity, brand strength, and a deep pipeline of new treatments. […]

View the basic LLY option chain and compare options of Eli Lilly and Company on Yahoo Finance.

Eli Lilly stock costs EUR 1,016.60 in weekend trading. That is EUR 0.10 below the last Xetra close o

Eli Lilly (NYSE:LLY) reported new clinical data on obesity drug Foundayo, diabetes candidate EloraTZP, and dermatitis therapy EBGLYSS, alongside plans for regulatory filings. The firm ended its cancer-drug collaboration with Foghorn Therapeutics, which Foghorn said is driving sizeable workforce reductions. A recent jury verdict found Lilly breached a collaboration agreement with Nektar Therapeutics, with damages awarded to Nektar. These fresh Foundayo, EloraTZP, and EBGLYSS milestones, plus...